Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.
Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).
Professor Graham Jackson (Newcastle, UK) gives an overview of his presentation on real world management of myeloma patients in the UK, with comments from Professor Sagar Lonial (Atlanta, USA). Professor Jackson… read more.
Professor Gordon Cook (Leeds, UK), Professor Guy Pratt (Birmingham, UK) and Professor Graham Jackson (Newcastle, UK) discuss the need for maintenance in the up-front setting for UK patients and the new data on… read more.
Dr Chris Fox (Nottingham, UK) highlights another presentation from Lymphoma SIG around the opportunities for genomic-driven change in lymphoma.
Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.
The 2019 annual meeting of the BSH showcased the best UK research with over 36 sessions covering a range of important issues related to the treatment of haematological… read more.
Faouzi Djebbari (Oxford) also gives his thoughts on the unmet needs of the newly diagnosed MM patient who is ineligble for stem cell transplantation.
Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.
IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…